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BACKGROUND: Some Medicare Part D enrollees whose
drug expenditures exceed a threshold enter a coverage
gap with full cost-sharing, increasing their risk for
reduced adherence and adverse outcomes.
OBJECTIVE: Toexaminecomorbiditiesanddemographic
characteristics associated with gap entry and exit.
DESIGN: We linked 2005–2006 pharmacy, outpatient,
and inpatient claims to enrollment and Census data. We
used logistic regression to estimate associations of 2006
gap entry and exit with 2005 medical comorbidities,
demographics, and Census block characteristics. We
expressed all results as predicted percentages.
PATIENTS: 287,713 patients without gap coverage,
continuously enrolled in a Medicare Advantage Part D
(MAPD) plan serving eight states. Patients who received a
low-income subsidy, could not be geocoded, or had no
2006 drug fills were excluded.
RESULTS: Of enrollees, 15.9% entered the gap, 2.6%
within the first 180 days; among gap enterers, only 6.7%
exited again. Gap entry was significantly associated with
female gender and all comorbidities, particularly demen-
tia (39.5% gap entry rate) and diabetes (28.0%). Among
dementia patients entering the gap, anti-dementia drugs
(donepezil, memantine, rivastigmine, and galantamine)
and atypical antipsychotic medications (risperidone, que-
tiapine, and olanzapine) together accounted for 40% of
pre-gap expenditures. Among diabetic patients, rosiglita-
zone accounted for 7.2% of pre-gap expenditures. Having
dementia was associated with twice the risk of gap exit.
CONCLUSIONS: Certain chronically ill MAPD enrollees
are at high risk of gap entry and exposure to unsubsi-
dized medication costs. Clinically vulnerable populations
should be counseled on how to best manage costs
through drug substitution or discontinuation of specific,
non-essential medications.
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services research; health economics.
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BACKGROUND
TheMedicarePartDPrescriptionBenefitwentintoeffectJanuary
2006, providing voluntary drug coverage to all Medicare benefi-
ciariesthroughprivateplanscontractingwithMedicare
1,2.P ar tD
coverageisofferedthroughalmost1900stand-aloneprescription
drug plans (PDPs) and over 1000 private Medicare Advantage
Part D plans (MAPDs)
3,4. Improved financial access to medica-
tions was expected to improve adherence to drug regimens and
outcomes. However, the standard Part D benefit included a
coverage gap designed to limit unnecessary utilization
5 and meet
budget constraints (Fig. 1). The gap is triggered annually with a
threshold leveloftotal participant and healthplancosts.While in
the gap, beneficiaries are responsible for the full cost of prescrip-
tion medications until another threshold of annual patient out-
of-pocket expenditures is reached and “catastrophic coverage”
(95% coverage with 5% coinsurance) begins. Although some
plans offer limited gap coverage, in 2008 71% of PDP and 49% of
MAPD plans had none
6.
A sizable proportion of patients enter the gap
7 and few reach
catastrophic coverage, so in order to manage treatment more
efficiently, it is important to understand which Medicare benefi-
ciaries are most likely to fall into the gap, particularly early in the
year. Individuals with chronic diseases requiring pharmaceutical
therapy are more likely to face long gaps in coverage
8. However,
most studies addressing this issue were based on pre-Part D
data
8–10; thus, they could not account for whether individuals
respond to benefit design by limiting drug utilization. Two studies
based on post-Part D data did find that patients with certain
conditions were more likely to enter the coverage gap, but each
study focused on a single condition (end-stage renal disease and
atrial fibrillation)
11,12. The extent to which other comorbidities
contribute to gap entry and exit has not yet been established.
Identifying specific medical conditions that put beneficiaries at
high risk of gap entry, especially early gap entry, and the
medications contributing most to pre-gap spending for those
beneficiaries, would allow clinicians to better focus discussions
with patients early in the benefit year on how to manage their
drug costs, e.g., through generic or therapeutic drug substitu-
tions or discontinuation of medications that do not appear to be
effective or that have widely recognized, potentially dangerous
side effects.
We used 2006 data on Medicare beneficiaries who were
continuously enrolled in a large, national for-profit MAPD and
subject to the Part D coverage gap to examine associations of
medical and psychiatric conditio n sa n dd e m o g r a p h i cc h a r a c t e r -
istics with the risk of gap entry and exit. We also examined which
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568medications purchased before gap entry account for the greatest
proportion of pre-gap spending.
METHODS
Sources of Data and Sample
Enrollment files and 2005–2006 inpatient, outpatient and Part
D pharmacy claims from a large MAPD plan located in eight
states were geocoded and linked to 2000 Census block data.
Comorbidities were identified using 2005 data; days until gap
entry and exit were calculated using 2006 data. The final
sample size was 287,713 after excluding beneficiaries who had
no 2006 drug fill (N=2,336) or were not continuously enrolled
during 2005–2006 (N=145,845); low-income subsidy qualifiers
not subject to a coverage gap (N=57,833); those with supple-
mental retirement benefits (N=111,032), other gap coverage
(N=48,373), or an atypical deductible amount (N=13,565);
and those missing geocode (N=3,187) or gender (N=1,020).
Measures
We examined whether the beneficiary: (1) entered the gap
during 2006; (2) entered the gap within the first 180 days of
2006; and (3) exited the gap before the end of 2006 (among
beneficiaries entering the gap during 2006). Predictors includ-
ed patient sex, age group, and indicators for the conditions
listed in Table 1. ICD-9-CM diagnosis codes used to identify
conditions were obtained from the Clinical Classifications
Software
13. All models controlled for fixed state effects, urban
residence (as a proxy for healthcare supply and geographic
proximity to care) and the characteristics of the population in
the beneficiary’s Census block listed in Table 2.
Statistical Analysis
Separate logistic regressions were estimated for each outcome.
We report the average predicted risk differences associated with
each comorbidity derived from these models (the mean difference
between probabilities predictedwiththecomorbidityindicator set
to1 vs.0,holding othercovariatevalues constant at their original
values). We simulated 99% confidence intervals (CIs) for these
Table 1. Characteristics of Study Population
Study population
(n=287,713)
National estimates for the population
aged ≥65 years (15,16)
NHANES (2005–2006)
Age group:
65–69 11% 28%
70–74 24% 23%
75–79 28% 20%
80–84 21% 15%
85+ 16% 14%
Female 60% 58% 49%
Living in urban area 94% —
Percent with:
Diabetes 20% 18% 19%
Hypertension 61% 53% 58%
Hyperlipidemia 45% — 53%
Coronary artery disease 17% 31% 12%
Mental health condition 8% — -
Dementia 4% — -
Osteoarthritis 20% — 52% (arthritis)
Rheumatologic arthritis 2% — 52% (arthritis)
Non-skin cancer 21% 21% 22% (skin and non-skin)
Chronic obstructive pulmonary disease 15% 10% 6% (emphysema) 8% (chronic bronchitis)
Congestive heart failure 7% — 10%
Atrial fibrillation/cardiac
dysrhythmias
16% — -
End-stage renal disease 1% — -
Stroke 10% 9% 11%
Peripheral vascular disease 7% — -
Key: NHANES = National Health and Nutrition Examination Survey
Figure 1. Standard 2006 benefits for Part D*.
569 Ettner et al.: Comorbidities and Part D Gap Entry JGIMrisk differences by assuming that coefficient estimates were
approximately multivariate normally distributed
14. Results were
similar when using generalized estimating equation models to
allow for clustering by census tract.
Our results were not sensitive to changes in the algorithms for
assigning comorbidity diagnoses. Therefore, we only report results
from the most inclusive algorithm, requiring only one inpatient or
outpatient claim with a diagnosis in the given category.
Finally, we explored which medications contributed most to
gap entry among patients with the comorbidities most closely
associated with gap entry (dementia and diabetes). This was done
by rank-ordering the medications used by gap enterers with these
comorbidities by the total (plan + patient) pre-gap expenditures
associated with each medication.
RESULTS
Population Characteristics
The study population was primarily women (60%) and urban
residents (94%) (Table 1). Approximately 50% were 75–84 years
old, with an additional 16% over 85. Comorbidities were
common, including hypertension (61%), non-skin cancer
(21%), diabetes (20%) and coronary artery disease (CAD)
(17%). The demographic and comorbidity distributions were
similar to 2006 national estimates for older adults, with the
exception that our study population was concentrated some-
what more heavily in the older age groups (Table 1)
15,16. The
study population was economically diverse, living in Census
blocks whose residents have median household incomes that
average $52,843 but with a large standard deviation (Table 2).
About one-quarter of Census block residents were non-white
and 6% spoke English poorly or not at all. Among this study
population, 15.92% entered the coverage gap in 2006, al-
though only 2.56% entered during the first 180 days.
Gap Entry
Table 3, Columns 2 and 3, present the estimated probabilities
of any 2006 gap entry. All of the medical conditions had
significant positive associations with the risk of gap entry,
although the magnitudes varied from modest (e.g., osteoar-
thritis) to extremely large (e.g., dementia). The risk differences
(RDs) are interpreted as percentage point increases. For
example, an absolute increase of 18.97% in the risk of gap
entry among patients with dementia represents an 18.97
percentage point increase, or more than doubling of the risk
of gap entry, relative to the unadjusted risk of 15.92%. Other
Table 3. Differences in Probability of Entry into Medicare Part D Coverage Gap, Entire Sample*
Gap entry any time during 2006
(unadjusted risk=15.92%)
a
Gap entry during first 180 days (unadjusted
risk=2.56%)
Risk difference 99% CI Risk difference 99% CI
Female 3.98% 3.63%, 4.34% 0.78% 0.62%, 0.94%
Age 70–74 −1.21% −1.85%, −0.57% −0.47% −0.79%, −0.16%
Age 75–79 −1.26% −1.87%, −0.66% −0.49% −0.79%, −0.19%
Age 80–84 −1.04% −1.61%, −0.22% −0.62% −0.94%, −0.32%
Age 85+ −0.91% −1.61%, −0.22% −0.73% −1.06%, −0.41%
Diabetes 11.60% 11.10%, 12.10% 2.60% 2.37%, 2.86%
Hypertension 4.33% 3.95%, 4.70% 0.51% 0.34%, 0.68%
Hyperlipidemia 2.56% 2.19%, 2.91% 0.22% 0.05%, 0.37%
Coronary artery disease 7.21% 6.70%, 7.74% 1.50% 1.28%, 1.75%
Mental health condition 6.29% 5.64%, 6.96% 1.72% 1.43%, 2.04%
Dementia 18.97% 17.80%, 20.15% 6.15% 5.51%, 6.85%
Osteoarthritis 0.73% 0.32%, 1.15% 0.19% 0.01%, 0.38%
Rheumatologic arthritis 4.84% 3.54%, 6.16% 1.67% 1.08%, 2.37%
Non-skin cancer 2.89% 2.47%, 3.31% 0.84% 0.65%, 1.04%
Chronic obstructive pulmonary disease 6.89% 6.38%, 7.43% 1.81% 1.58%, 2.07%
Congestive heart failure 6.44% 5.73%, 7.16% 1.43% 1.13%, 1.74%
Atrial fibrillation 2.36% 1.90%, 2.83% 0.33% 0.14%, 0.53%
End-stage renal disease 8.05% 6.55%, 9.60% 2.14% 1.52%, 2.83%
Stroke 5.61% 5.01%, 6.19% 1.12% 0.87%, 1.37%
Peripheral vascular disease 2.66% 2.05%, 3.29% 0.40% 0.16%, 0.67%
* N=287,713. All estimates were significant at p≤0.01
aBeneficiaries aged 65–69 are the reference age group. We used logistic regression to model the probability of each outcome, controlling for the full set of
comorbidities in addition to a constant term, age group, sex, fixed state effects, urban residence and the percentages of Census block residents who have
less than a high school education; are white, African American, Asian, Native American, and another race; and who speak no English or speak English
poorly (vs. speak English well). The reference category for each comorbidity is therefore individuals without that particular comorbidity.
Table 2. Characteristics of Census-Block Population (N=126,977
Census blocks)
Mean or %
Median household income of Census block
residents
$52843 (SD=
$23093)
% Census block residents who:
Have less than a high school education 26%
Speak no English 2%
Speak English poorly 4%
Speak English well 94%
% Census block residents who are:
White 77%
African American 6%
Asian 7%
Native American 2%
Other race 11%
Not born in U.S. 16%
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11.60%), end-stage renal disease (RD=8.05%), coronary artery
disease (RD=7.21%), chronic obstructive pulmonary disease
(RD=6.89%), congestive heart failure (RD=6.44%) and mental
health conditions (RD=6.29%). Greater age was associated
with significantly lower probability of gap entry, while women
had about a one-quarter higher chance of gap entry than men.
Early Gap Entry
Table 3, columns 4 and 5, present similar estimates for early
gap entry. The associations remained statistically significant
for all comorbidities. Furthermore, while the risk differences
were smaller in absolute magnitudes, the relative effects were
generally larger because the unadjusted risk of early gap entry
is only 2.56%. For example, dementia was associated with
more than a tripling of the risk of early gap entry (RD=6.15%,
implying that overall risk jumps to almost 9%). Diabetes, end-
stage renal disease, chronic obstructive pulmonary disease,
and rheumatologic arthritis were associated with a doubling or
near-doubling of the risk. Associations of early gap entry with
sociodemographic characteristics showed patterns similar to
any gap entry.
Gap Exit Among Patients Who Entered the Gap
Table 4 presents differences in the conditional risk of gap exit.
Among all beneficiaries entering the gap, only 6.68% exited the
gap and reached catastrophic coverage by the end of 2006.
Predictors of gap exit among gap enterers were slightly different
from predictors of gap entry. For example, rheumatologic arthri-
tisincreasedthelikelihoodofgapentrybylessthanone-third,yet
almost doubled the conditional likelihood of gap exit. Other
comorbidities associated with a substantially higher conditional
probability of gap exit were dementia, mental health conditions,
congestive heart failure and diabetes.
Medication Use Patterns Among Dementia
and Diabetes Patients Entering the Gap
Tables 5 and 6 show the medications that were the most
important drivers of gap entry for patients with dementia and
diabetes. Of the twelve medications jointly accounting for half
of pre-gap drug expenditures, four (donepezil, memantine,
galantamine, and rivastigmine) were anti-dementia agents,
while another three (risperidone, quetiapine, and olanzapine)
were atypical antipsychotics. Notably, 66.32% of dementia
patients entering the gap were on at least one anti-dementia
drug. As the average cost of these drugs was also high ($4.86
per day), the four dementia drugs together accounted for
32.28% of pre-gap drug expenditures among this subgroup.
Table 4. Differences in Probability of Exit from Medicare Part D
Coverage Gap Among Patients Who Entered the Gap*
Any 2006 gap exit (unadjusted risk
=6.68%)
a
Risk
difference
99% CI
Female 0.68% 0.04%, 1.34%
Age 70–74 −0.43% −1.71%, 0.79%
Age 75–79 0.00% −1.22%, 1.13%
Age 80–84 −0.51% −1.79%, 0.67%
Age 85+ −0.54% −1.88%, 0.69%
Diabetes 2.15% 1.44%, 2.90%
Hypertension −0.70% −1.48%, 0.04%
Hyperlipidemia −1.36% −2.04%,−0.72%
Coronary artery disease 0.37% −0.34%, 1.14%
Mental health condition 2.55% 1.62%, 3.58%
Dementia 7.57% 6.17%, 9.15%
Osteoarthritis 0.10% −0.59%, 0.85%
Rheumatologic arthritis 4.49% 2.39%, 6.98%
Non-skin cancer 1.87% 1.16%, 2.83%
Chronic obstructive pulmonary
disease
1.13% 0.40%, 1.95%
Congestive heart failure 2.50% 1.54%, 3.54%
Atrial fibrillation 0.05% −0.66%, 0.78%
End-stage renal disease 1.76% 0.06%, 3.75%
Stroke 1.23% 0.42%, 2.07%
Peripheral vascular disease 0.37% −0.52%, 1.36%
* N=45,815
aBeneficiaries aged 65–69 are the reference age group. We used logistic
regression to model the probability of the outcome, controlling for the full
set of comorbidities in addition to a constant term, age group, sex, fixed
state effects, urban residence and the percentages of Census block
residents who have less than a high school education; are white, African
American, Asian, Native American, and another race; and who speak no
English or speak English poorly (vs. speak English well). The reference
category for each comorbidity is therefore individuals without that
particular comorbidity.
Table 5. Medications Contributing Most to Pre-Gap Drug Expenditures of Beneficiaries with Dementia
Medication Pre-Gap Expenditures for
Drug
% of Total Pre-Gap
Expenditures
% of Dementia Patients Using Drug Prior to
Gap Entry
Average Cost For a 30-Day
Supply
Donepezil $1,902,696 19.58% 49.74% $145.20
Memantine $844,794 8.70% 29.80% $125.10
Clopidogrel $330,861 3.41% 12.32% $122.40
Risperidone $267,247 2.75% 8.60% $159.90
Quetiapine $237,272 2.44% 8.95% $135.30
Pantoprazole $220,116 2.27% 9.80% $114.00
Olanzapine $217,209 2.24% 5.57% $225.60
Galantamine $194,508 2.00% 5.38% $148.50
Rivastigmine $194,195 2.00% 4.82% $164.70
Escitalopram $174,204 1.79% 10.61% $70.20
Atorvastatin $170,519 1.76% 9.14% $85.20
Lovastatin $150,510 1.55% 18.09% $29.70
Medications shown account for 50.48% of total pre-gap drug costs among 4,091 patients with dementia who enter the gap in 2006
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accounted for a high proportion of costs. The top three drugs
(rosiglitazone, clopidogrel and metformin) accounted for 7.21%,
4.58% and 3.56% of pre-gap expenditures, respectively. Almost
half as many patients were using rosiglitazone (20.54%), a third-
line oral agent with an average daily cost of $4.28, as were using
metformin (45.69%), a first-line agent with an average daily cost
of $0.84.
DISCUSSION
One-quarter of Medicare patients who lacked drug coverage in
2005 signed up for a Part D plan in 2006, implying that 3.4
million seniors acquired drug benefits due to the program
7.
Moreover, previously uninsured patients saved 60% of their
drug costs through the new benefit
7. At the same time, the Part
D benefit design included a coverage gap to limit the cost of the
new drug benefit, as well as provide an incentive to limit
overuse of non-essential drugs
5. Given the heterogeneous need
for prescription medications among Medicare beneficiaries,
this design may disproportionately penalize populations who
already have high costs of care. In addition to putting patients
at financial risk, adherence to medication regimens (and as a
result, outcomes) may suffer if the 100% cost sharing imposed
in the coverage gap discourages compliance
17. Physicians who
make a routine practice of prescribing lower-cost medications
first and discontinuing those that do not appear to be effective
may not only improve their patients’ adherence to more
essential medications by keeping them out of the coverage
gap, but also avoid exposing their patients to side effects
associated with potentially unnecessary medications
18.
To efficiently allocate their time counseling patients about drug
costs, physicians need to know which beneficiaries would benefit
most from discussions about changing their medication regi-
mens. This study examined the correlates of Medicare Part D
coverage gap entry in order to identify subgroups of patients who
may be at particular risk of gap entry and hence high out-of-
pocket costs that might discourageadherenceto drug regimens
19.
Our study found an extremely high risk of gap entry among
patients with certain clinical and demographic profiles. Of the
conditions studied, dementia had the strongest association with
gap entry, followed by diabetes, end-stage renal disease, CAD,
COPD and congestive heart failure. We also identified an
association of gap entry with female gender, perhaps because
women are more likely to seek and adhere to treatment
20.A sa n
example derived from our data, an average 67-year-old woman
with diabetes and a typical set of comorbidities (hypertension,
hyperlipidemia, coronary artery disease, depression) would have
a 54% probability of falling into the Medicare Part D coverage gap
during 2006 and being exposed to the full cost of her medication
regime. If this patient fell into the gap, she would have a 11%
chance of exiting again and qualifying for catastrophic coverage.
In the meantime, however, she would have incurred more than
$3,600 in total out-of-pocket drug expenditures. Similarly, the
probability of gap entry for a 75-year-old woman with dementia
and depression would be 48%, with a conditional probability of
gap exit of 20%.
Dementia may prevent patients from optimizing their health-
care choices, e.g., leading them or their surrogates to continue
to buy brand-name drugs rather than switch to generics or
failing to ask about therapeutic substitutes
21. Alternatively,
patients with dementia may be entering the gap earlier because
they are using expensive anti-dementia medications. The latter
interpretation is supported by the drug utilization patterns
observed among dementia patients who entered the coverage
gap. The possibility that anti-dementia medications may be
causing elderly patients to fall into the Medicare Part D coverage
gap is disturbing, given the limited evidence of effectiveness of
these drugs
22,23. Another notable finding was the high use of
Table 6. Medications Contributing Most to Pre-Gap Drug Expenditures of Beneficiaries with Diabetes
Medication Pre-Gap Expenditures
for Drug
% of Total Pre-Gap
Expenditures
% of Diabetes Patients Using Drug
Prior to Gap Entry
Average Cost For a 30-
Day Supply
Rosiglitazone $2,716,653 7.21% 20.54% $128.40
Clopidogrel $1,726,883 4.58% 16.43% $120.90
Metformin $1,341,259 3.56% 45.69% $25.20
Pioglitazone $1,196,860 3.18% 9.81% $142.20
Atorvastatin $1,172,725 3.11% 14.95% $85.50
Lovastatin $1,080,550 2.87% 29.20% $31.20
Simvastatin $969,869 2.57% 10.95% $127.20
Carvedilol $868,512 2.30% 9.05% $100.20
Ezetimibe/Simvastatin
combination
$851,199 2.26% 10.65% $78.90
Pantoprazole $837,923 2.22% 10.18% $113.10
Lisinopril $733,939 1.95% 35.24% $17.70
Valsartan $669,291 1.78% 9.97% $62.40
Amlodipine $614,675 1.63% 11.13% $54.90
Insulin glargine $609,278 1.62% 9.87% $89.10
Donepezil $521,810 1.38% 4.17% $144.60
Glyburide $511,407 1.36% 21.48% $20.70
Long-acting Diltiazem $484,040 1.28% 10.11% $39.00
Fluticasone and salmeterol
inhalation powder
$476,768 1.27% 5.16% $158.10
Long-acting Nifedipine $434,152 1.15% 7.12% $51.30
Risedronate $387,101 1.03% 5.27% $73.80
Gabapentin $358,228 0.95% 8.32% $53.70
Medications shown account for 49.25% of total pre-gap drug costs among 16,079 patients with diabetes who enter the gap in 2006
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olanzapine, for which “black box warnings” had been issued as
early as 2005 to caution against their use in elderly patients
with dementia
24. More than one-fifth (23%) of dementia patients
entering the gap were taking one of these three drugs and this
figure rose to 36% among those living in skilled nursing
facilities. Less than one-quarter (23%) of these patients had a
schizophrenia-related diagnosis. These findings suggest that
healthcare providers should make a special effort to assist
patients with dementia in making choices about drug treat-
ments to protect their financial as well as clinical interests.
Although the magnitude of its association with gap entry was
smaller for diabetes (RD=11.60%) than dementia (RD=18.97),
the far higher prevalence of diabetes (20% vs. 4%) implies that
the overall system impact is likely to be much greater. Although
patterns of medication use among diabetic patients entering the
gap raise fewer clinical concerns than those seen among
dementia patients, cost considerations remain. Generic sub-
stitutes for brand-name drugs are widely available for some
classes of diabetes medications (e.g., metformin and sulfonylur-
eas) and even for those with no generic substitutes (e.g., TZDs),
therapeutic substitutions are often possible. For example,
metformin has an average daily cost less than one-quarter as
high as that of rosiglitazone and is usually the first-line agent of
choice. Yet in our data, the ratio of metformin to rosiglitazone
use was only about 2:1, and 11% of diabetes patients on
rosiglitazone were taking it as a single agent, suggesting that
in some cases it may have been used as a first-line medication.
Thus some patients without contraindications could possibly be
switched to metformin.
Our conclusions should be interpreted in light of several
study limitations. We may be overstating the associations of gap
entry with comorbidities for which claims diagnoses are under-
coded and only the most severely ill patients are identified as
having the comorbidity
25. Undercoding may be particularly
common for dementia, as Alzheimer’s disease alone (accounting
for roughly 60% of all dementia) has a prevalence rate of 13%
among the elderly. Conversely, inclusion of mild cases for other
comorbidities could lead to understating associations with gap
entry, because estimates reflect averages across diverse levels of
severity.
Our MAPD patients were somewhat older than the national
elderly population, suggesting that rates of gap entry and exit
could have been higher in our study. We chose to study only
MAPD patients, since data for PDP patients (while available to
us) were limited to pharmacy claims, which do not provide
reliable diagnosis information. Compared with the MAPD
patients, on average the PDP patients in our database had
similar gender distribution, were three years younger, used
about two fewer prescriptions per year, and had lower rates of
generic (vs. branded) and mail-order drug use, suggesting that
they might be at greater risk of gap entry. Nonetheless, as MAPD
plans have more influence than PDP plans on the practice
pattern of their physicians, MAPD enrollees are the most likely
target population for interventions encouraging physicians to
more actively manage the drug utilization of their patients
26.
We use health plan prices and have data from only eight
states, predominantly in the western half of the country.
Nonetheless, the for-profit MAPD plan we studied is among the
largest in the country and the majority of MAPD enrollees are in
for-profit plans
27. Over time patients might become more aware
of the coverage gap and modify their behavior accordingly,
although several studies show that people still do not under-
stand the gap or make economically preferred choices
28,29.
Finally, medication analyses are inherently a “moving target”
because new medications constantly come onto the market, old
medications become generic, and new evidence on drug effec-
tiveness and substitutions is disseminated. Thus, findings
based on 2006 data should be interpreted in light of any
changes to the prescription drug market that may have
occurred since then.
Although inadequate drug coverage is hardly unique to the
Medicare population and in fact the Part D program greatly
improved coverage for many older Americans, its unique
“coverage gap” feature does highlight the risks of financial
exposure to drug costs. The financial burden associated with
coverage gap entry could lead to unacceptable tradeoffs. Studies
examining the effect of pre-Part D drug benefit caps found that
patients often discontinued use, “stretched” their medications or
cut back on other necessities because of cost
30–33.P a r tD
coverage gap entry also has implications for medication adher-
ence
29 and (since medications are important in controlling
chronic conditions) ultimately for health outcomes. Together
with the desire of patients to receive more information about
management of drug costs from their physicians
34–36, our
findings suggest that medication cost counseling interventions
focusing on these clinically vulnerable subpopulations may be
warranted
37.
Physician-patient discussions about the expense and unde-
sirable side effects of particular medications are one approach to
managing outpatient drug therapy and controlling costs. Other
systematic strategies might include disease management inter-
ventions, monitoring and feedback of physician prescribing
patterns, use of formularies with utilization tools (e.g., prior
authorization policies), or collaborative care involving pharma-
cists. A recent systematic review concluded that most of these
strategies are moderately effective in changing medication use
38,
although tiered formulary interventions may also cause discon-
tinuation of essential and/or cost-effective medications
39 and
many of these strategies require an electronic medical record
(currently used by only a minority of U.S. physicians
40 in order
to optimize results. One possible next step would be to take
high-risk patients and randomize them to a high-level organi-
zational intervention to help them better manage their drugs.
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